Navstel
FDA Approves Retinal Implant for Rare Genetic Eye Disease »
"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
Read the FDA Approves Retinal Implant for Rare Genetic Eye Disease article »
Navstel
CLINICAL PHARMACOLOGY
Pharmacokinetics
The components of NAVSTEL® (balanced salt ophthalmic solution) Solution are normally found in aqueous humor with the exception of hypromellose. Hypromellose is a high molecular weight polymer and is not expected to be absorbed into ocular tissues.
Clinical Studies
Results from clinical studies in patients undergoing cataract surgery demonstrated that NAVSTEL® (balanced salt ophthalmic solution) Solution was an effective irrigating solution for anterior segment surgical procedures and significantly reduced turbulent flow during phacoemulsification. Results from an additional clinical study demonstrated that NAVSTEL® (balanced salt ophthalmic solution) was an effective irrigating solution for posterior segment surgical procedures.
Last reviewed on RxList: 9/3/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Navstel Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
WebMD Daily
Get breaking medical news.
Updated & New
